Latest News - Market Wire News

Market Wire News Hottest Alerts Newsletter

Market Wire News — Tue, 06 Oct 2026 03:35:36 -0400

Subscribe to Market Wire News newsletter for instant real-time stock alerts, breaking financial news, trending stocks, and portfolio updates delivered to your email & mobile.

Market Wire News Trending Stocks

Market Wire News — Tue, 06 Oct 2026 03:35:36 -0400

Track today's hottest trending stocks on NASDAQ, NYSE, OTCMKTS & Canadian markets. See massive % gainers, real-time movers, volumes, and linked breaking news updates.

Market Wire News Investor Awarenewss

Market Wire News — Tue, 06 Oct 2026 03:35:36 -0400

Stock Promoter, Investor Relations, Investor Awareness, Market Wire News, investor brand advertisement services, plans and pricing.

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews July 10, 2026 09:00:00 am

PR Newswire — Fri, 10 Jul 2026 09:00:00 -0400

IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals PR Newswire Ionis Pharmaceuticals lost more than 20% before the market opened -- a decline of nearly $17 -- after its Phase-3 CARDIO-TTRansform trial missed i...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews July 09, 2026 08:57:00 pm

PR Newswire — Thu, 09 Jul 2026 20:57:00 -0400

Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS) Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of a Pending Investigation Into Ionis Pharmaceuticals (IONS)...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews July 09, 2026 02:00:00 am

Business Wire — Thu, 09 Jul 2026 02:00:00 -0400

– Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with eplontersen monotherapy – – Favorable safety profile consistent with p...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews July 06, 2026 07:00:00 am

Business Wire — Mon, 06 Jul 2026 07:00:00 -0400

- Topline data from REVEAL anticipated in 2H 2027 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evaluating obudanersen (ION582), an investigational RNA-targeted medi...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews June 25, 2026 02:59:00 am

Business Wire — Thu, 25 Jun 2026 02:59:00 -0400

- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access and country-specific regulatory environments - - Ionis to independently commercialize zilganersen in the U.S. assuming FDA approval - Ionis Pharmaceuticals, Inc. (Nasdaq: IO...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews June 24, 2026 02:37:00 pm

Business Wire — Wed, 24 Jun 2026 14:37:00 -0400

– Proven to deliver significant and robust triglyceride reductions – – Only treatment for sHTG indicated to reduce the risk of acute pancreatitis – – Ionis’ first independent commercial launch in a prevalent condition – ...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews June 08, 2026 07:00:00 am

Business Wire — Mon, 08 Jun 2026 07:00:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective immediately. “We are pleased to welcome Dr. Hantson to the board,” said Joseph Losca...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews June 04, 2026 07:00:00 am

Business Wire — Thu, 04 Jun 2026 07:00:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during four oral presentations at upcoming medical conferences. Data will be presen...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews May 28, 2026 04:45:00 am

Business Wire — Thu, 28 May 2026 04:45:00 -0400

– Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care – – 49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews May 14, 2026 07:05:00 am

Business Wire — Thu, 14 May 2026 07:05:00 -0400

- Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response - - Robust reductions in tau pathology were observed across all studied doses, with results general...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews May 04, 2026 07:05:00 am

Business Wire — Mon, 04 May 2026 07:05:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. ...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews April 29, 2026 07:00:00 am

Business Wire — Wed, 29 Apr 2026 07:00:00 -0400

- TRYNGOLZA ® (olezarsen) showed increasing demand in FCS driven by strong launch execution – - Olezarsen sNDA accepted by the FDA for Priority Review; sHTG launch preparations on track – – Increasing annual TRYNGOLZA peak net sales guidance to >$3...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews April 28, 2026 02:06:00 am

Business Wire — Tue, 28 Apr 2026 02:06:00 -0400

– Regulatory submission supported by Phase 3 B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B - – Breakthrough Therapy designation added to Fast Track Designation, recognizing potential for substanti...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews April 21, 2026 07:00:00 am

Business Wire — Tue, 21 Apr 2026 07:00:00 -0400

– New data highlight potential treatment benefit across multiple AxD symptom domains, reinforcing zilganersen’s positive impact on people living with this rare, often fatal neurological disease – – PDUFA date set for September 22, 2026 – ...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews April 15, 2026 07:05:00 am

Business Wire — Wed, 15 Apr 2026 07:05:00 -0400

Webcast scheduled for Wednesday, April 29 at 8:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first quarter 2026 financial results and highlight progress o...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews March 23, 2026 07:00:00 am

Business Wire — Mon, 23 Mar 2026 07:00:00 -0400

– PDUFA date set for September 22, 2026 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an investigational RNA-targeted medi...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews March 09, 2026 07:00:00 am

Business Wire — Mon, 09 Mar 2026 07:00:00 -0400

– Lynne Parshall and Joseph Wender to retire at end of term in June 2026 and Peter Reikes to join Ionis Board – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will ...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews February 27, 2026 07:00:00 am

Business Wire — Fri, 27 Feb 2026 07:00:00 -0500

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE and OASISplus studies. Results will be presented a...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews February 26, 2026 07:00:00 am

Business Wire — Thu, 26 Feb 2026 07:00:00 -0500

– PDUFA date set for June 30, 2026 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen for severe hypertriglyceridemi...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews February 25, 2026 07:00:00 am

Business Wire — Wed, 25 Feb 2026 07:00:00 -0500

- TRYNGOLZA ® generated $108 million in net product sales in 2025, the first year of launch – - Olezarsen sHTG launch preparations on track, sNDA submitted - - Exceeded 2025 financial guidance, 2026 guidance reflects commitment to independently deliver a steady cad...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews February 17, 2026 02:58:00 pm

Business Wire — Tue, 17 Feb 2026 14:58:00 -0500

Webcast scheduled for Wednesday, February 25 at 8:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. The live webcast, previously scheduled for 11:30 a.m. E...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews February 11, 2026 07:05:00 am

Business Wire — Wed, 11 Feb 2026 07:05:00 -0500

Webcast scheduled for Wednesday, February 25 at 11:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2025 financial results a...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews February 04, 2026 07:30:00 am

GlobeNewswire — Wed, 04 Feb 2026 07:30:00 -0500

Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersen The high-dose regimen of nusinersen also slowed neurodegeneration more rapidly, as measured by neuro...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews January 21, 2026 07:00:00 am

Business Wire — Wed, 21 Jan 2026 07:00:00 -0500

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission (EC) has approved DAWNZERA™ (donidalorsen) in the European Union (EU) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adu...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews January 12, 2026 11:05:00 am

GlobeNewswire — Mon, 12 Jan 2026 11:05:00 -0500

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA 1 Biogen is dedicated to partnering with the SMA community to advance care through scientific inn...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews January 12, 2026 07:00:00 am

Business Wire — Mon, 12 Jan 2026 07:00:00 -0500

– TRYNGOLZA® (olezarsen) outperforms expectations, achieved 2025 preliminary U.S. net product sales of $105M* as first FDA-approved treatment for FCS; sNDA for sHTG submitted for review – – Increasing annual TRYNGOLZA peak net sales guidance to >$2B for sHTG...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews January 07, 2026 02:15:00 am

Business Wire — Wed, 07 Jan 2026 02:15:00 -0500

– Primary endpoint met in both trials – – Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate – – Chronic hepatitis B (CHB) accounts for ~56% of liver cancer cases and affects more than 250...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews January 06, 2026 07:05:00 am

Business Wire — Tue, 06 Jan 2026 07:05:00 -0500

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 44 th Annual J.P. Morgan Healthcare Conference at 8:15 a.m. PT on Tuesday, January 13, 2026. A live webcast of the presentation can be acc...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews December 02, 2025 07:00:00 am

Business Wire — Tue, 02 Dec 2025 07:00:00 -0500

– First and only investigational medicine for this rare, often fatal neurological condition – – On track to submit new drug application (NDA) in Q1 2026 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Adm...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews December 01, 2025 07:00:00 am

Business Wire — Mon, 01 Dec 2025 07:00:00 -0500

– On track to submit supplemental new drug application by end of year – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olezarsen as an adjunct to diet to redu...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews November 17, 2025 06:00:00 am

GlobeNewswire — Mon, 17 Nov 2025 06:00:00 -0500

Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved 12mg dose regimen 1 Final European Commission decision expected in January 2026 SMA is a...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews November 14, 2025 04:05:00 pm

GlobeNewswire — Fri, 14 Nov 2025 16:05:00 -0500

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx™ drug delivery system. ...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews November 14, 2025 07:00:00 am

Business Wire — Fri, 14 Nov 2025 07:00:00 -0500

Recommendation based on breadth of clinical evidence demonstrating significant HAE attack rate reduction with DAWNZERA European Commission decision expected in Q1 2026 Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews November 13, 2025 12:39:00 am

Business Wire — Thu, 13 Nov 2025 00:39:00 -0500

- Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 Convertible Notes prior to or at maturity Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $700.0 million aggregate principal amount of 0.00% Convertible Senior Notes due ...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews November 11, 2025 04:05:00 pm

Business Wire — Tue, 11 Nov 2025 16:05:00 -0500

- Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 Convertible Notes prior to or at maturity Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $700.0 million aggreg...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews November 08, 2025 09:40:00 am

Business Wire — Sat, 08 Nov 2025 09:40:00 -0500

– Up to 72% placebo-adjusted mean reduction in fasting triglyceride levels at six months, with reductions sustained through 12 months – – 86% of olezarsen-treated patients achieved triglyceride levels less than 500 mg/dL, below the risk threshold for acute pancreatiti...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews November 06, 2025 08:00:00 am

Business Wire — Thu, 06 Nov 2025 08:00:00 -0500

DAWNZERA showed durable efficacy, demonstrating 94% overall mean HAE attack rate reduction at one year in OASISplus open-label extension study Patients in OASISplus switch study achieved 68% improvement in mean HAE attack rate compared to prior prophylactic therapy one year after switchin...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews October 27, 2025 07:00:00 am

Business Wire — Mon, 27 Oct 2025 07:00:00 -0400

– Ionis to host webcast on Saturday, November 8 at 3:00 p.m. ET to discuss results – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that detailed data from the landmark pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyc...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews October 23, 2025 02:10:00 pm

Business Wire — Thu, 23 Oct 2025 14:10:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the company was named as a top employer to work for by Science magazine in its annual Top Employer survey of the biopharmaceutical and related industries. In its first year of eligibility for the award, Ionis was ranked second based...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews October 21, 2025 08:00:00 am

Business Wire — Tue, 21 Oct 2025 08:00:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., Ionis’ chief executive officer, was awarded the 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society (OTS), a nonprofit organization that fosters academia and industry-based re...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews October 16, 2025 07:05:00 am

Business Wire — Thu, 16 Oct 2025 07:05:00 -0400

Webcast scheduled for Wednesday, October 29 at 11:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, October 29 th at 11:30 a.m. Eastern Time to discuss its third quarter 2025 financial results and progres...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews October 07, 2025 07:00:00 am

Business Wire — Tue, 07 Oct 2025 07:00:00 -0400

– Two independent launches underway in less than nine months, with two more on track for 2026 – – Growing pipeline of wholly owned medicines in neurology and cardiometabolic disease and leading technology for next-generation medicines – – Clear p...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews September 23, 2025 04:30:00 pm

GlobeNewswire — Tue, 23 Sep 2025 16:30:00 -0400

CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company’s supplemental New Drug Application (sNDA) for the high dose regimen of nusinersen fo...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews September 22, 2025 07:00:00 am

Business Wire — Mon, 22 Sep 2025 07:00:00 -0400

– First and only investigational medicine to demonstrate a clinically meaningful and disease-modifying impact on this rare, often fatal neurological condition – – NDA submission planned in Q1 2026 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) tod...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews September 19, 2025 07:00:00 am

Business Wire — Fri, 19 Sep 2025 07:00:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS). The approval follow...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews September 18, 2025 07:40:01 am

GlobeNewswire — Thu, 18 Sep 2025 07:40:01 -0400

Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs) ThecaFlex DRx™ has the potential to be a new, convenient way to administer medicines to patients li...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews September 12, 2025 07:00:00 am

Business Wire — Fri, 12 Sep 2025 07:00:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today celebrated 10 years of Surf Away+, an inclusive adaptive event for rare neurological disease communities. Originally created with the goal of providing people with spinal muscular atrophy (SMA) access to adaptive surfing, the event has expanded t...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews September 09, 2025 07:00:00 am

Business Wire — Tue, 09 Sep 2025 07:00:00 -0400

- Pivotal Phase 3 REVEAL study enrollment on track to complete in 2026 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 for the treatment of Angelman syndrome (AS), ...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews September 08, 2025 04:00:00 pm

Business Wire — Mon, 08 Sep 2025 16:00:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will host Ionis Innovation Day on Tuesday, October 7, 2025, in New York. The agenda will feature presentations from members of the Ionis leadership team as well as a key thought leader in the treatment of severe hypertriglycer...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews September 02, 2025 04:00:00 pm

Business Wire — Tue, 02 Sep 2025 16:00:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 H.C. Wainwright 27 th Annual Global Investment Conference on Mon...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews September 02, 2025 07:00:00 am

Business Wire — Tue, 02 Sep 2025 07:00:00 -0400

– Up to 72% (p<0.0001) placebo-adjusted mean reduction in fasting triglycerides – – 85% (p=0.0002) reduction in acute pancreatitis events, the first and only time achieved for the treatment of sHTG – – Favorable safety and tolerability profi...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews July 30, 2025 07:00:00 am

Business Wire — Wed, 30 Jul 2025 07:00:00 -0400

- TRYNGOLZA TM delivers $19 million in net product sales in the second quarter 2025 - - Donidalorsen approval in hereditary angioedema (HAE) anticipated next month; Ionis’ second independent launch - - Phase 3 data from the pivotal CORE and CORE2 studies in severe hyper...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews July 25, 2025 07:15:00 am

Business Wire — Fri, 25 Jul 2025 07:15:00 -0400

– Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZA – – European Commission decision expected by Q4 2025 – Ionis Pharmaceuti...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews July 21, 2025 07:00:00 am

Business Wire — Mon, 21 Jul 2025 07:00:00 -0400

– Patients switched to donidalorsen without increased breakthrough attacks and experienced further reductions in mean attack rate from baseline – – 84% of patients surveyed preferred donidalorsen over their prior treatment – – Donidalorsen is c...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews July 16, 2025 07:05:00 am

Business Wire — Wed, 16 Jul 2025 07:05:00 -0400

Webcast scheduled for Wednesday, July 30 at 11:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 30 th at 11:30 a.m. Eastern Time to discuss its second quarter 2025 financial results and progress on ...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews June 27, 2025 10:00:23 am

GlobeNewswire — Fri, 27 Jun 2025 10:00:23 -0400

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA ® (nusinersen) Final results from the landmark NURTURE study high...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews June 25, 2025 07:31:00 am

Business Wire — Wed, 25 Jun 2025 07:31:00 -0400

– Investigational salanersen (ION306/BIIB115) developed using novel Ionis antisense chemistry with the potential to achieve high efficacy and once-yearly dosing – – Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substant...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews June 25, 2025 07:30:37 am

GlobeNewswire — Wed, 25 Jun 2025 07:30:37 -0400

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA) Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neur...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews June 12, 2025 09:00:00 am

Business Wire — Thu, 12 Jun 2025 09:00:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role. ...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews June 11, 2025 07:00:00 am

Business Wire — Wed, 11 Jun 2025 07:00:00 -0400

- Completion of enrollment anticipated in 2026 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine fo...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews May 19, 2025 07:00:00 am

Business Wire — Mon, 19 May 2025 07:00:00 -0400

– Olezarsen met the primary endpoint with a statistically significant mean reduction in triglycerides versus placebo at 80 mg and 50 mg doses – – Olezarsen met all key secondary endpoints – – Olezarsen demonstrated a favorable safety and tole...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews May 06, 2025 07:05:00 am

Business Wire — Tue, 06 May 2025 07:05:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. ...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews April 30, 2025 07:00:00 am

Business Wire — Wed, 30 Apr 2025 07:00:00 -0400

- Encouraging start to first independent launch with TRYNGOLZA TM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Co...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews April 29, 2025 07:00:00 am

Business Wire — Tue, 29 Apr 2025 07:00:00 -0400

– Despite currently available treatment options, the majority of surveyed adults with HAE reported making tradeoffs in their daily lives due to the unexpected and unpredictable nature of HAE attacks – – Opportunity exists for more consistent use of tools to support tr...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews April 16, 2025 07:05:00 am

Business Wire — Wed, 16 Apr 2025 07:05:00 -0400

Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30 th at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results. The webcas...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews April 03, 2025 07:05:00 am

Business Wire — Thu, 03 Apr 2025 07:05:00 -0400

– Webinar scheduled for Monday, April 14 at 11:00 a.m. ET – Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14 th at 11:00 a.m. ET focused on the risks, clinical presentation and significant unmet medical needs a...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews March 26, 2025 07:00:00 am

Business Wire — Wed, 26 Mar 2025 07:00:00 -0400

– Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world – – Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – Ionis Pharmaceuticals, ...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews March 11, 2025 06:00:00 pm

Business Wire — Tue, 11 Mar 2025 18:00:00 -0400

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted m...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews March 10, 2025 07:00:00 am

Business Wire — Mon, 10 Mar 2025 07:00:00 -0400

– Second major approval for WAINZUA, which is marketed in the U.S. as WAINUA™ – – EU approval based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus plac...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews February 20, 2025 07:00:00 am

Business Wire — Thu, 20 Feb 2025 07:00:00 -0500

– Data also show significant and clinically meaningful improvements in quality-of-life measures in new analyses from Phase 3 and Phase 2 clinical program – –With a PDUFA date of August 21, 2025, donidalorsen positioned to be Ionis’ second independent commercial...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews February 19, 2025 07:00:00 am

Business Wire — Wed, 19 Feb 2025 07:00:00 -0500

- First independent launch underway following TRYNGOLZA TM approval - - Second independent launch on track with donidalorsen PDUFA August 21, 2025 - - WAINUA TM U.S. launch delivering accelerating sequential growth - - Ionis exceeds 2024 financial guidance and prov...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews February 05, 2025 07:05:00 am

Business Wire — Wed, 05 Feb 2025 07:05:00 -0500

Webcast scheduled for Wednesday, February 19 at 11:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19 th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial re...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews January 23, 2025 07:30:54 am

GlobeNewswire — Thu, 23 Jan 2025 07:30:54 -0500

CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the application for a high...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews January 13, 2025 08:00:00 am

PR Newswire — Mon, 13 Jan 2025 08:00:00 -0500

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum PR Newswire – Accelerating value creation with numerous commercial, regulatory and pipeline milestones –...

$IONS Ionis Pharmaceuticals Inc #MWN #BreakingNews January 08, 2025 04:11:00 pm

PR Newswire — Wed, 08 Jan 2025 16:11:00 -0500

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference PR Newswire CARLSBAD, Calif. , Jan. 8, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia , Ph.D., chief executive officer, will present a compa...